Carboplatin: 338 Real Stories

338 stories match carboplatin. 332 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage III Lung Squamous Cell CarcinomaLung Cancer

Stage 3 squamous cell lung cancer: complete remission on tislelizumab monotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Squamous lung cancer markers: P40 positive, TTF-1/Napsin A negative, Ki-67 75%. PD-1/PD-L1 testing was not done.

As of April 2024, enhanced CT, tumor-marker decline, and clinical assessment supported complete remission by iRECIST after chemoimmunotherapy and tislelizumab monotherapy.

PubMed Central
OutcomeCancer-Free / NED
Luna, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV ROS1 Lung Adenocarcinoma: Luna's Patient Story

Patient Info: Luna, Female, 50s | Stage IV

Biomarkers: ROS1 rearrangement; EGFR negative; ALK negative

Metastatic Site: liver; bones

Luna had Stage IV ROS1-positive lung adenocarcinoma with liver and bone metastases. After progression on initial chemotherapy, crizotinib led to tumor shrinkage and controlled her cancer for almost 12 years as of March 2025.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: liver

The cancer progressed after transformation to small cell lung cancer, and she died 49 months after the original diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung cancer: managing pembrolizumab-induced myasthenia gravis

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Anti-acetylcholine receptor antibody elevated; TSH elevated during immune-related adverse event workup; cancer biomarkers not reported

At 9 months after the immune-related myasthenia gravis presentation, lung cancer remained in complete response while she continued low-dose prednisolone, pyridostigmine, levothyroxine, and nighttime NIV.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage 4 lung adenocarcinoma with RET fusion responding to pralsetinib

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: RET fusion

Metastatic Site: pleura

As of March 2025, he had recovered from grade 3 Pneumocystis jirovecii pneumonia, restarted pralsetinib, and had no progressive disease or recurrence of adverse events over 13 months.

PubMed Central
OutcomeResponding Well
Chance, who was diagnosed with Stage II Breast CancerBreast Cancer

Facing Triple-Negative Breast Cancer: Chance’s Story

Patient Info: Chance, Female, Under 40 | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of February 2025, Chance described follow-up after Stage II BRCA1-associated triple-negative breast cancer and stated that she did not currently have cancer, while continuing close surveillance.

The Patient Story
OutcomeCancer-Free / NED
Kelly, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III Triple-Negative Breast Cancer: Kelly's Survivor Story

Patient Info: Kelly, Female, Under 40 | Stage III

Biomarkers: Triple-negative breast cancer; no inherited cancer gene mutation found.

As of February 2025, Kelly identified as a Stage IIIC triple-negative breast cancer survivor after neoadjuvant chemotherapy, double mastectomy with reconstruction, and radiation, and was using her experience to support others through TNBC Thrivers.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Small Cell Lung CancerLung Cancer

Stage 4 small cell lung cancer with paraneoplastic neurological syndrome

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Paraneoplastic antibody panel positive for anti-Hu, anti-AMPH, anti-Ri

Metastatic Site: left axillary lymph nodes

Over 2 years of follow-up, CT showed stable complete response, tumor markers stayed normal, no new metastases appeared, and neurological symptoms did not worsen.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Fatal Multiorgan Failure After Pembrolizumab-Based Treatment for Metastatic Lung Cancer

Patient Info: Anonymized, female | Stage IV

She died less than 12 hours after hospital presentation with rapidly progressive multiorgan failure one week after the first pembrolizumab-based treatment cycle; immune-related toxicity was strongly suspected, although the rapid decline limited full evaluation.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung Adenocarcinoma With Rare Skin Metastasis to the Neck

Patient Info: Anonymized, male, 50s | Stage IV

Metastatic Site: neck skin

The lung cancer later spread to the neck skin, and he died during the following year after stopping further treatment.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Advanced Non-Small Cell Lung Cancer With ERBB2 and TP53 Mutations

Patient Info: Anonymized, male, 50s | Stage IV

Biomarkers: ERBB2 exon 20 Y772-A775dup mutation; TP53 mutation; PD-L1 TPS 0%

Metastatic Site: liver, bone, both lungs

Imaging after treatment showed stable disease, and he remained in good condition while continuing maintenance pemetrexed and bevacizumab.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage III Small Cell Lung CancerLung Cancer

Stage III small cell lung cancer with paraneoplastic optic disc swelling

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: anti-CV2/CRMP-5 positive; anti-Hu positive

Eighteen months after diagnosis, there was no evidence of cancer recurrence. Optic disc swelling had fully resolved after steroid treatment, with preserved visual function.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Metastatic Lung Adenocarcinoma With a Serious Immune-Therapy Pituitary Complication

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: No detected EGFR, ALK, ROS1, RET, MET or HER2 alterations

Metastatic Site: brain, meninges, skull, bone, pituitary

The cancer had progressed to extensive brain, skull and bone involvement after several treatments. Steroid treatment improved the severe thirst, high urine output and other symptoms from immune-related hypophysitis.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Small Cell Lung CancerOvarian Cancer

Small Cell Ovarian Cancer Causing Acute Kidney Injury

Patient Info: Anonymized, Female | Stage III

Biomarkers: Somatic SMARCA4 alterations; no germline SMARCA4 pathogenic variant

Combined pembrolizumab, carboplatin, and paclitaxel was continued after marked radiologic improvement, with an excellent PET-CT response documented after 13 cycles.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Limited-stage SCLC with paraneoplastic syndrome: complete response

Patient Info: Anonymized, Female, 50s

Biomarkers: SCLC markers: TTF-1 and synaptophysin positive, Ki-67 ~85%; anti-CV2/CRMP5 and anti-SOX1 antibodies positive.

Remission at 6 years after carboplatin/etoposide chemotherapy, thoracic radiation, and prophylactic cranial irradiation for limited-stage SCLC with paraneoplastic cerebellar degeneration.

PubMed Central
OutcomeCancer-Free / NED